|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
PLENARY PAPER
From the Department of Molecular and Experimental
Medicine, The Scripps Research Institute, La Jolla, CA; the First
Department of Medicine, University of Vienna, Austria; and the
Department of Medicine, Mayo Clinic, Rochester, MN.
To assess the relationship between venous thrombosis and plasma
glucosylceramide (GlcCer) or phosphatidylethanolamine (PE), plasma
levels of GlcCer and PE were determined for 70 venous thrombosis patients referred for evaluation and 70 healthy blood donors. The mean
GlcCer level, but not the PE level, was lower in patients versus controls (4.9 vs 6.5 µg/mL [P = .0007] and 66 vs 71 µg/mL [P = .48], respectively). As a measure of
relative risk, the odds ratio for deep vein thrombosis in subjects with
GlcCer levels below the 10th percentile of controls was 5.7 (95% CI,
2.3-14). To assess the influence of glycolipids on anticoagulant
response to activated protein C (APC):protein S in modified prothrombin time assays, the effects of depleting endogenous plasma GlcCer by
glucocerebrosidase treatment or of adding exogenous purified GlcCer or
other neutral glycolipids to plasma were tested. Glucocerebrosidase treatment reduced plasma sensitivity to APC:protein S in parallel with
GlcCer reduction. Exogenously added GlcCer and the homologous Glc-containing globotriaosylceramide (Gb3Cer), but not
galactosylceramide, dose-dependently prolonged clotting times of normal
plasma in the presence, but not absence, of APC:protein S, which
suggests that GlcCer or Gb3Cer can enhance protein C pathway
anticoagulant activity. In studies using purified proteins,
inactivation of factor Va by APC:protein S was enhanced by
GlcCer alone and by GlcCer in multicomponent vesicles
containing phosphatidylserine and phosphatidylcholine. These results
suggest that the neutral glycolipids GlcCer and Gb3Cer may
directly contribute to the anticoagulant activity of the protein C
pathway and that deficiency of plasma GlcCer may be a risk factor for
venous thrombosis.
(Blood. 2001;97:1907-1914) Poor anticoagulant response to
activated protein C (APC), termed APC resistance, is detected in 20%
to 50% of patients with venous thrombosis,1 and it can be
present in patients with normal factor V genotype2-4, with
the factor V polymorphism, Arg506Gln,5-7 or with a variety
of acquired conditions, eg, oral contraceptive use8 or
auto-antibody against APC.9 APC resistance is also
associated with increased risk of ischemic stroke in subjects with
normal Arg506-factor V.10,11 Severe deficiency of
protein C or protein S causes life-threatening
thrombosis.12-15 Thus, the protein C pathway provides a
major physiologic anticoagulant mechanism for down-regulation of
thrombin generation in which APC proteolytically inactivates factors Va
and VIIIa.16
Blood coagulation reactions and the anticoagulant protein C
pathway are stimulated by phospholipid membrane
surfaces.17 However, procoagulant and anticoagulant
complexes may be differentially affected by different membrane
phospholipid components.18-20 Because we found that high
density lipoprotein (HDL) exhibits anticoagulant cofactor activity for
APC:protein S,21 we decided to further evaluate the
influence of plasma lipids and lipoproteins on the protein C pathway.
Plasma lipoproteins contain glycolipids as well as
phospholipids.22-24 Glycolipids can play critical roles as
bioregulators of a variety of processes such as cell
proliferation, cell mobility, and apoptosis.23 Glycolipid
molecules present their highly varied saccharide residues on the
surface of lipoprotein particles as well as on cell surfaces, thereby
exposing saccharides to interactions with other cells, antibodies,
bacterial toxins, and viral envelope proteins.23 Several
hundred glycolipids are known. However, the relevance of glycolipids to
the blood coagulation system is currently unknown. Studies of the
relationship between glycolipids and risks of venous thrombosis or of
the influence of glycolipids on the APC:protein S anticoagulant pathway
have not been reported.
This paper presents studies of the relationship between venous
thrombosis and plasma levels of glucosylceramide (GlcCer)
(glucocerebroside) and phosphatidylethanolamine (PE). Studies presented
here show that a remarkable percentage of venous thrombosis patients
have low plasma GlcCer levels and, furthermore, that GlcCer and
globotriaosylceramide (Gb3Cer) enhance the anticoagulant action of
APC:protein S both in plasma and in purified reaction mixtures
containing factor Va. Consequently, these studies suggest that GlcCer
deficiency is a potential risk factor for venous thrombosis and give
rise to the novel broad concept that neutral glycolipids may contribute to regulation of thrombin generation, blood coagulation, and thrombosis.
Patient and control groups
The control group comprised 70 healthy individuals (41 women and 29 men) without a history of VTE or arterial thromboembolism who had a
mean age of 42 ± 14 years (range, 19-85 years old). These healthy
laboratory blood donors were routine volunteers who were not taking
oral contraceptives or estrogen replacement therapy. For an additional
determination of normal GlcCer levels, a panel was collected at The
Scripps Research Institute, La Jolla, CA, from 40 healthy adult donors
(20 male and 20 female) with a median age of 35.8 ± 7.1 years
(range, 19-56 years). Healthy subjects gave informed consent for
studies approved by appropriate institutional review. Blood samples
were obtained from routine venipuncture after an overnight fast, then
mixed with 0.129 M sodium citrate (vol:vol, 9:1). Plasma was
prepared by centrifugation at 2000g for 20 minutes at room temperature
and then stored at Lipid analysis
Material from the GlcCer HPLC peak eluting at 4.1 minutes showed one
spot on TLC corresponding to purified GlcCer, and the spot, as well as
reference GlcCer, were stained by the Digestion of plasma GlcCer by glucocerebrosidase Endogenous plasma GlcCer was hydrolyzed by 2 different glucocerebrosidases ( -glucosidase) (Sigma): recombinant
glucocerebrosidase (specific activity, 1.35 U/mg) or almond-derived
glucocerebrosidase (specific activity, 2.85 U/mg), which are relatively
specific hydrolases for GlcCer. Plasma was incubated with varying
concentrations of glucocerebrosidase for 3 minutes, and then lipid was
extracted from plasma aliquots using chloroform and methanol for GlcCer determination by HPLC. In these studies, determining hydrolysis of
GlcCer by glucocerebrosidase, the concentration of PE, which was not
hydrolyzed by glucocerebrosidase, was used as internal standard
for lipid recovery. In parallel, prothrombin time (PT) assays
(see below) were performed using aliquots of
glucocerebrosidase-treated plasma.
Anticoagulant response to APC:protein S Modified dilute PT-based assays were performed as previously described.21 Briefly, 7.5 µL test plasma was mixed with fibrinogen (final concentration, 0.6 mg/mL) and APC (final concentration, 8.7 nM) plus protein S (final concentration, 28 nM) or buffer and incubated for 3 minutes at 37°C for a total volume of 100 µL. Clotting times were measured after addition of 50 µL recombinant human tissue factor (Innovin; Dade, Miami, FL) diluted 1:40 in Tris (tris[hydroxymethyl] aminomethane)-buffered saline containing 0.5% bovine serum albumin (TBSA) and 30 mM calcium dichloride (CaCl2). Baseline clotting times without addition of APC:protein S were also determined. For studies of the effects of glycolipid vesicles or glucocerebrosidase treatment on clotting assays, a 1:64 dilution of Innovin was used in the presence or absence of APC and protein S. In the study of the effect of glucocerebrosidase, 13 nM APC and 42 nM protein S were employed.Preparation of glycolipid vesicles To prepare extruded glycolipid vesicles, dried glycolipids GlcCer, Gb3Cer, galactosylceramide (GalCer) (Sigma), and
LacCerwere suspended at 100 µg/mL in tris buffered saline
(TBS) at room temperature, vortexed 5 minutes, and passed
through a 0.22-µm filter (Millipore Corporation, Bedford, MA).
Concentrations of glycolipids recovered after filtration were
determined by HPLC analysis as described above.
Large unilamellar multicomponent vesicles were prepared generally as described.27 Appropriate aliquots of PC, PS, and GlcCer were mixed and dried under nitrogen. The lipid mixture was hydrated at a concentration of 6.25 mM lipid in TBS and freeze-thawed 10 times using liquid nitrogen, and the solution of vesicles was passed 15 times through a 0.22-µm filter. Concentrations of glycolipid recovered after filtration were determined by HPLC analysis as described above. PC concentration was determined by an enzymatic colorimetric method (Phospholipids B kit; Wako Chemical USA, Inc, Richmond, VA). Factor Va inactivation assay To study the time course of factor Va inactivation by APC:protein S, mixtures containing final concentrations of 21.5 µM GlcCer vesicles, 21.5 µM control PC vesicles, or buffer and final concentrations of 6 nM APC, 18 nM protein S, and 1.5 nM factor Va with 5 mM CaCl2 were incubated at 37°C. Aliquots were withdrawn at various times, and the reaction was quenched by adding ethylenediamine tetraacetic acid (EDTA) prior to determination of residual factor Va activity. For the various lipid mixtures (wt/wt)PC
alone, 90% PC/10% GlcCer, 90% PC/10% PS, and 80% PC/10% PS/10%
GlcCervesicles at varying concentrations were incubated with final
concentrations of 1 nM APC, 18 nM protein S, and 1.5 nM factor Va for 3 minutes at 37°C, and then the reaction was quenched by adding EDTA.
The residual factor Va activity was quantitated using PT clotting
assays and standard log-log calibration curves of clotting time versus
factor Va concentration generated using purified factor Va and factor V-deficient plasma.21
Statistical analysis Statistical analyses were performed using Prism 3.0 software (Graph Pad Software, Inc, San Diego, CA) to determine correlations using the 2-tailed Pearson test with 95% CI. Mean and SD values for various plasma lipid levels were derived from distributions based on logarithm transformation of observed values. The SD between 2 groups was determined using the Student t test (unpaired, 2-tailed with 95% CI) (Prism 3.0), and the difference was considered significant when P .05.
Plasma GlcCer and PE in patients with DVT A method to quantitate both GlcCer and PE in plasma extracts using HPLC was developed and validated as described in "Patients, materials, and methods." When GlcCer and PE in fasting plasma lipid extracts from 70 patients with DVT and 70 controls were quantitated and when logarithm-transformed data were analyzed as the mean (± SD), the plasma GlcCer level was 4.89 (3.1-7.1) µg/mL in patients compared with 6.54 µg/mL (4.4-9.7) in controls (Figure 1A), and the difference was statistically significant (P = .0007). As a measure of relative risk, the odds ratio for DVT in subjects with GlcCer levels below the 10th percentile of controls was 5.7 (95% CI, 2.3-14).
In contrast to GlcCer, there was no significant difference between patients and controls for the mean ± SD plasma PE levels (P = .48): 70.6 µg/mL (50-100) for patients and 65.5 µg/mL (42-102) for controls (Figure 1D). As previously determined25 for another healthy control panel of 40 blood donors from The Scripps Research Institute, the mean level of GlcCer was 6.9 µg/mL (range, 4.2-14.7 µg/mL), and the mean level of PE was 66 µg/mL (range, 16.1-156 µg/mL). These values do not differ significantly from the values of our 70 controls (Figures 1A,D) from the University of Vienna and the Mayo Clinic (P = .71 and P = .31, respectively). Moreover, the mean plasma GlcCer value reported here for each control group is comparable to previously reported normal values,28 thus validating our quantification of plasma GlcCer. The influence of gender on plasma GlcCer levels was analyzed. There were no statistically significant differences between mean values of plasma GlcCer for male or female controls (P = .54) or for male and female patients (P = .67) (data not shown), thereby showing no influence of sex on plasma GlcCer levels. A slight influence of age on plasma GlcCer level was noted for the entire group of 140 subjects (P = .014, r2 = 0.043) and for the 70 controls (P = .038, r2 = 0.062), but not for the 70 patients (P = .78) (data not shown). This small influence of age was insufficient to alter the statistically significant differences between patients and controls. Patients were separated into those experiencing thrombosis at less than 44 years of age and those who were at least 45 years old. When each group of patients was compared with the corresponding controls, the mean GlcCer level was significantly lower for younger thrombosis patients (4.4 µg/mL) compared with controls (6.9 µg/mL) (Figure 1B) (P = .0003), but not for older thrombosis patients (5.2 µg/mL) compared with controls (6.1 µg/mL) (Figure 1C) (P = .33). When patients and controls who were less than 45 years old were analyzed, the odds ratio for DVT for GlcCer levels below the 10th percentile value of controls was 5.2 (95% CI, 1.4-19.4). This odds ratio of 5.2 was similar to that of 5.7 for the overall group of 70 thrombosis patients compared with 70 controls. For the groups of people aged 44 years or younger, the mean ages of patients and controls at the time of plasma sampling were 34.4 and 32.4 years old, respectively, and were not significantly different (P = .25). Comparison of the GlcCer values for patients below the 10th percentile value of controls who were at least 45 years old gave an odds ratio for venous thrombosis of 1.87 (95% CI, 0.45-7.7) (P = .33) (Figure 1C). Although statistical significance for a difference in GlcCer between the older patients and controls was lacking, it may be noteworthy that 7 (17%) of 45 patients had low GlcCer values below 3.3 µg/mL compared with 2 (6%) of 29 controls, which suggests that plasma GlcCer deficiency also occurs in older patients with venous thrombosis. For each of the 2 age groups above or below 45 years old, the mean PE values were not statistically significantly different between patients with venous thrombosis and controls (P = .57 and 0.15, respectively) (data not shown). Glucocerebrosidase effect on blood coagulation and anticoagulant response to APC:protein S To assess the direct influence of GlcCer in plasma on procoagulant reactions and on anticoagulant activities of APC:protein S, endogenous GlcCer in plasma was hydrolyzed by varying amounts of recombinant glucocerebrosidase. In parallel, glucocerebrosidase-treated plasma was analyzed for its coagulation properties and for loss of GlcCer. Recombinant glucocerebrosidase decreased the concentration of plasma GlcCer by approximately 50% in a dose-dependent fashion (Figure 2). The anticoagulant response to APC:protein S, as reflected by prolongation of observed clotting times (Figure 2), was reduced in parallel to reduction of endogenous GlcCer concentrations. Similar results showing parallel decrease of plasma GlcCer and decreased response to APC:protein S were obtained in similar experiments using purified almond-derived glucocerebrosidase added to plasma (data not shown), proving that this effect was independent of the source of glucocerebrosidase. PE levels were not affected by this enzyme (plus or minus 10%), showing that significant phospholipid hydrolysis had not occurred. Interestingly, in the absence of APC:protein S, recombinant glucocerebrosidase did not affect the baseline clotting times (Figure 2). Thus, depletion of endogenous GlcCer by specific hydrolytic enzymes is associated with decreased anticoagulant response to APC:protein S.
Influence of exogenous glycolipids on anticoagulant response of plasma to APC:protein S Several purified glycolipids, including GlcCer, LacCer, Gb3Cer, and GalCer, in vesicles were added to plasma, which was then assayed as described.21 When GlcCer was added to plasma in the presence of APC:protein S, it caused dose-dependent marked prolongation of the modified PT assay (Figure 3). Similar effects of GlcCer causing clotting time prolongation in the presence, but not absence, of APC:protein S were observed in factor Xa-1-stage assays performed without addition of exogenous phospholipids (data not shown). When APC alone was added without protein S, addition of GlcCer caused much less clotting time prolongation compared with APC plus protein S (Figure 3). When protein S alone was added in the absence of APC, GlcCer had no effect on clotting times (data not shown). Gb3Cer, a trisaccharide-containing glycolipid in which the Glc unit of GlcCer is extended by two Gal units, had activity very similar to GlcCer (Figure 3). However, GalCer, which simply has Gal in place of Glc, did not enhance APC:protein S action and had no effect on baseline clotting times (Figure 3). LacCer, a disaccharide-containing glycolipid, also had no effect on the anticoagulant response. Neither 0-100 µg/mL D-Glc alone nor ceramide alone affected APC:protein S anticoagulant response (data not shown). Thus, the anticoagulant enhancement of APC action by neutral glycolipids was stereo-specific for the saccharide moieties.
Correlation of anticoagulant response to APC:protein S with plasma GlcCer levels To assess the correlation between plasma GlcCer levels and procoagulant reactions or anticoagulant response, clotting assays using diluted tissue factor were performed21 in the presence and absence of APC and protein S. For this analysis, plasmas from subjects known to carry Q506-factor V were excluded because of the significant influence of this polymorphism on anticoagulant response to APC. The anticoagulant response, as reflected by the clotting time in the presence of APC:protein S, was correlated with GlcCer levels for thrombosis patients (P = .0035, r = 0.45, n = 37) (Figure 4A), but not for controls (P = .55, n = 45) (Figure 4B). Further analysis of subgroups showed that this anticoagulant response correlated with GlcCer for male patients with thrombosis (P = .0025, r = 0.65, n = 19) but not for female patients with thrombosis (P = .21, r = 0.31, n = 18) (data not shown). Analysis was done to correlate between baseline clotting times for thrombosis patients (P = .038, r = 0.29, n = 50) (Figure 4C) and controls (P = .18, r = 0.20, n = 50) (Figure 4D).
Direct effect of GlcCer on purified factor Va inactivation To test whether GlcCer vesicles have a direct effect on factor Va inactivation by APC:protein S in purified system, purified proteins were used to study the time course of factor Va inactivation. Factor Va inactivation by APC:protein S was enhanced by GlcCer vesicles compared with PC vesicles or buffer alone (Figure 5A), indicating that GlcCer vesicles can directly enhance factor Va inactivation. Experiments were also performed to characterize the anticoagulant cofactor potency of GlcCer incorporated into multicomponent phospholipid vesicles. When such vesicles containing 10% GlcCer were used to stimulate inactivation of purified factor Va by APC:protein S, PC/GlcCer vesicles were more active than PC vesicles, but less active than PC/PS vesicles (Figure 5B). Incorporation of 10% GlcCer into 80% PC/10% PS vesicles enhanced factor Va inactivation compared with 90% PC/10% PS vesicles (Figure 5B). The apparent potency of these tricomponent GlcCer/PC/PS vesicles was approximately an order of magnitude greater than PC/PS vesicles (Figure 5B). Thus, GlcCer can significantly directly enhance inactivation of purified factor Va by APC:protein S.
Based on our interest in the influence of plasma lipids and lipoproteins on the antithrombotic protein C pathway,18-21,25 we established HPLC-based methods to quantitate various plasma phospholipids including cardiolipin, PS, and PE.25 The HPLC methodology used for PE analysis also permitted quantitation of the neutral glycosphingolipid GlcCer. When the influence of GlcCer on anticoagulant response to APC:protein S was studied, we found that depletion of endogenous GlcCer by addition of glucocerebrosidase to normal pooled plasma proportionately reduces sensitivity to APC:protein S (Figure 2), while addition of exogenous GlcCer to normal plasma dose-dependently enhances the anticoagulant response without affecting baseline clotting time (Figure 3). Thus, plasma GlcCer appeared to act like an anticoagulant cofactor for APC:protein S, leading us to hypothesize that GlcCer would influence anticoagulant activity by enhancing APC:protein S in vivo and that GlcCer deficiency may predispose to thrombosis. To test the hypothesis that plasma GlcCer deficiency is a marker or risk factor for thrombosis, plasma GlcCer and PE mean levels of 70 patients with DVT were compared to those of 70 healthy controls. This comparison showed a remarkably lower mean level of GlcCer, but not of PE, in patients compared with controls (P = .0007 and P = .48, respectively). Plasma GlcCer levels did not differ by gender in patients or in controls. As a measure of relative risk, the odds ratio for DVT in subjects with low plasma GlcCer levels below the 10th percentile of controls was 5.7 (95% CI, 2.3-14). For those patients under age 45 in whom hereditary risk factors might play a more easily identifiable role, the difference between plasma GlcCer values for patients and controls was remarkable (P = .0003), and the odds ratio for venous thrombosis for subjects with GlcCer below the 10th percentile of controls was 5.2 (95% CI, 1.40-19.4). These observations suggest that plasma GlcCer deficiency may be a marker or a risk factor for venous thrombosis and that younger age may be an important factor for low plasma GlcCer associated with venous thrombosis. In suggesting that low plasma GlcCer could be a potential risk factor rather than simply a marker for venous thrombosis, we note that experiments here demonstrate biological plausibility for the ability of GlcCer to directly enhance the anticoagulant action of APC:protein S in both the plasma milieu and in reaction mixtures containing purified clotting factors. In normal plasma, depletion of endogenous GlcCer by enzymatic treatment proportionately decreased GlcCer levels and anticoagulant response to APC:protein S, and furthermore, when purified GlcCer was added to plasma, it dose-dependently enhanced this anticoagulant response. In studies using purified proteins, GlcCer directly enhanced inactivation of purified factor Va by APC:protein S. The direct anticoagulant effects of GlcCer were apparent for vesicles containing GlcCer in the absence and presence of PS. The ability of glycolipids to enhance APC:protein S anticoagulant
activity in plasma demonstrated specificity for the conformation and
composition of the saccharide moieties. Anticoagulant activity appeared
to be, at least in part, specific for D-Glc linked covalently to Cer
because neither D-Glc nor ceramide alone was anticoagulantly active
while GlcCer was very active and because GalCer was also relatively
inactive. The effects of extending the saccharide unit attached to Cer
were complex because GlcCer (Glc The major plasma neutral glycolipids that are associated with each
major class of plasma lipoproteins, very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and HDL, include GlcCer, LacCer,
Gb3Cer, and Gb4Cer and have plasma levels of approximately 10, 5.5, 2.1, and 2.8 µM, respectively.28 Their biological
activities are partially determined by their sugar head groups and
partially by their lipid moieties. LacCer accumulation in
atherosclerotic lesions is caused by oxidized LDL and is associated
with atherosclerosis via stimulation of smooth muscle cell
proliferation by superoxide generation.29
Interestingly, in contrast to LacCer, neither GlcCer nor Gb3Cer
supports this atherogenic reaction.29 We speculate that
GlcCer and Gb3Cer could suppress thrombin generation which contributes
to development of atherothrombosis by enhancing the APC:protein S
anticoagulation system. Notably, LacCer does not possess this
anticoagulant property. Thus, from these perspectives, LacCer may be
considered an atherogenic glycolipid, while GlcCer and Gb3Cer may be
anti-atherothrombogenic glycolipids. Moreover, this specific activity
of oxidized LDL on selective accumulation of LacCer provides
another case, in addition to that presented here, where a biologic
activity of these 3 neutral glycolipids, each containing Glc linked to
Cer by How does GlcCer directly enhance the anticoagulant action of APC:protein S? APC cleaves the heavy chain of factor Va at R506 and then R306 and perhaps R679,30 and protein S and phospholipids are known to accelerate factor Va inactivation by selectively promoting the otherwise slow phospholipid-dependent cleavage at R306.31 In purified protein systems, GlcCer might directly accelerate cleavage at R306, R506, or R679 in factor Va by APC in the presence of protein S by binding to one or more of these proteins. In the plasma milieu there are additional potential mechanisms for GlcCer and its analogues. Protein S can abrogate the ability of factor Xa to protect factor Va from APC cleavage,32 and factor Va residues 493-506 provide binding sites for protein S and factor Xa.33 It is also possible that GlcCer might enhance the ability of protein S to compete better with factor Xa for binding factor Va. Cleavage of factor V at R506 augments the anticoagulant cofactor activity of factor V for APC-dependent inactivation of factor VIIIa, and GlcCer might affect these anticoagulant reactions.34 Moreover, it is possible that GlcCer associates with another plasma component that itself directly enhances APC:protein S anticoagulant activity, in which case the anticoagulant effect of GlcCer on APC:protein S would be an indirect one. Extensive studies are needed to define the mechanisms of action of GlcCer as an anticoagulant cofactor. When data were analyzed for correlations between plasma GlcCer levels and anticoagulant response to APC:protein S, several patterns were observed (Figure 4). For all patients with venous thrombosis and normal factor V genotype, ie, those who did not carry the APC-resistant Q506-factor V, the anticoagulant response to APC:protein S correlated with GlcCer levels. However, analysis of patient subgroups showed that this correlation was significant only for males, and there was no statistically significant correlation for controls. The variability of these correlations is puzzling because in vitro adjustments of plasma levels of GlcCer in pooled normal plasma affect the anticoagulant response to APC:protein S. Because GlcCer is a minor lipid component of all classes of plasma lipoproteins, it is possible that one or more minor apolipoproteins also play functional roles in the expression of APC:protein S anticoagulant activity in conjunction with plasma GlcCer. If so, one wonders what are the effects on plasma lipoproteins of the in vitro manipulations that alter GlcCer levels. Because the metabolism of GlcCer is linked to that of other plasma neutral glycolipids, eg, Gb3Cer, which could also affect anticoagulant response, correlations might preferably be sought between anticoagulant response and the combined plasma levels of GlcCer and Gb3Cer. Finally, plasma GlcCer low levels might reflect defects in cellular GlcCer availability that relate to cell-dependent antithrombotic mechanisms which affect risks of thrombosis. Our observations that two neutral glycolipids, GlcCer and Gb3Cer, can influence the anticoagulant action of APC:protein S and that low plasma GlcCer is a potential risk factor for venous thrombosis provide the surprising implication that neutral glycolipids may influence blood coagulation reactions.17 It is widely recognized that activation of the blood coagulation system is enhanced by charged phospholipid membrane surfaces as is the expression of the anticoagulant protein C pathway. However, procoagulant and anticoagulant complexes may be differently affected by different membrane phospholipid components or lipoproteins. For instance, the anionic phospholipid phosphatidylserine very effectively enhances prothrombin activation by factor Xa and factor Va complexes. VLDL can potentially support prothrombinase activity,35-37 whereas HDL, particularly HDL2 (H.D., J.A.F., and J.H.G., unpublished data, May 2000), can act as an anticoagulant cofactor by enhancing protein S-dependent APC activity.21 Thus, the blood coagulation pathways and the counterbalancing protein C anticoagulant system can be differentially modulated by various lipids and lipoproteins. Studies presented here raise the possibility that any number of the several hundred glycolipids might contribute to up-regulation or down-regulation of thrombin generation. The ability of GlcCer and Gb3Cer to modulate plasma sensitivity to APC:protein S may be clinically relevant. Pregnancy and oral contraceptive usage reduce the anticoagulant response to APC.8,38,39 Estradiol lowers GlcCer synthase, the primary enzyme that synthesizes GlcCer, and it also raises glucosidase activity,40 suggesting that plasma GlcCer levels might be reduced by pregnancy or oral contraceptive use. Some anticancer drugs are also known to reduce GlcCer synthesis,41,42 and tamoxifen decreases GlcCer synthesis in cultured cells.42 Because tamoxifen use is also associated with increased risk of venous thrombosis,43 lowered GlcCer may reduce the sensitivity of tamoxifen-treated patients to APC:protein S and thereby increase risk of venous thrombosis. The importance of vascular bed-specific signals and molecules as risk factors for vascular bed-specific thrombosis has been recently highlighted.44 Given the possibility of vascular bed-specific expression of any number of several hundred glycolipids, it is tempting to speculate that tissue bed-specific glycolipids may modulate both procoagulant and anticoagulant reactions. For example, negatively charged sulfatides can exert both procoagulant and anticoagulant activities.45,46 Thus, there are a number of intriguing implications of the observation that the neutral glycolipids GlcCer and Gb3Cer enhance APC:protein S anticoagulant response and that a low level of plasma GlcCer appears to be a potential risk factor for venous thrombosis.
We are grateful to Professor Ernest Beutler and the Stein Endowment Fund (La Jolla, CA) for support of the HPLC/ELSD system and to Ms Aimie Goto Ogawa and Ms Young Mee Lee for skillful technical assistance. We appreciate the support and encouragement of this project by Professor Klaus Lechner at the University of Vienna, Austria.
Submitted June 26, 2000; accepted December 7, 2000.
Supported in part by grants RO1HL21544 and R37HL52246 from the National Institutes of Health, Bethesda, MD; a grant from the Stein Endowment Fund; and a postdoctoral fellowship from the American Heart Association, Western States Affiliate.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: John H. Griffin, Dept of Molecular and Experimental Medicine, The Scripps Research Institute, MEM180, 10550 North Torrey Pines Rd, La Jolla, CA 92037; e-mail: jgriffin{at}scripps.edu.
1.
Svensson PJ, Dahlbäck B.
Resistance to activated protein C as a basis for venous thrombosis.
N Engl J Med.
1994;330:517-522 2. Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state. Thromb Res. 1996;82:235-244[CrossRef][Medline] [Order article via Infotrieve].
3.
Rodeghiero F, Tosetto A.
Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
Ann Intern Med.
1999;130:643-650
4.
de Visser MC, Rosendaal FR, Bertina RM.
A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.
Blood.
1999;93:1271-1276 5. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67[CrossRef][Medline] [Order article via Infotrieve]. 6. Greengard JS, Sun X, Xu X, Fernández JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 1994;343:1361-1362[Medline] [Order article via Infotrieve]. 7. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994;343:1535-1536[CrossRef][Medline] [Order article via Infotrieve]. 8. Rosing J, Middeldrop S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C. Lancet. 1999;354:2036-2040[CrossRef][Medline] [Order article via Infotrieve].
9.
Zivelin A, Gitel S, Griffin JH, et al.
Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C.
Blood.
1999;94:895-901
10.
Fisher M, Fernández JA, Ameriso SF, et al.
Activated protein C resistance in ischemic stroke not due to factor V arginine506
11.
van der Bom JG, Bots ML, Haverkate F, et al.
Reduced response to activated protein C is associated with increased risk for cerebrovascular disease.
Ann Intern Med.
1996;125:265-269 12. Branson HE, Katz J, Marble R, Griffin JH. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet. 1983;2:1165-1168[Medline] [Order article via Infotrieve]. 13. Seligsohn U, Berger A, Abend M, et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med. 1984;310:559-562[Abstract]. 14. Mahasandana C, Suvatte V, Marlar RA, Manco-Johnson MJ, Jacobson LJ, Hathaway WE. Neonatal purpura fulminans associated with homozygous protein S deficiency. Lancet. 1990;335:61-62[Medline] [Order article via Infotrieve]. 15. Jalbert LR, Rosen ED, Moons L, et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest. 1998;102:1481-1488[Medline] [Order article via Infotrieve].
16.
Marlar RA, Kleiss AJ, Griffin JH.
Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme.
Blood.
1982;59:1067-1072 17. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 1991;30:10363-10370[CrossRef][Medline] [Order article via Infotrieve].
18.
Smirnov MD, Esmon CT.
Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C.
J Biol Chem.
1994;269:816-819 19. Smirnov MD, Ford DA, Esmon CT, Esmon NL. The effect of membrane composition on the hemostatic balance. Biochemistry. 1999;38:3591-3598[CrossRef][Medline] [Order article via Infotrieve]. 20. Fernández JA, Kojima K, Petaja J, Hackeng TM, Griffin JH. Cardiolipin enhances protein C pathway anticoagulant activity. Blood Cells Mol Dis. 2000;26:115-23[CrossRef][Medline] [Order article via Infotrieve]. 21. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernández JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest. 1999;103:219-227[Medline] [Order article via Infotrieve]. 22. Dawson G, Kruski AW, Scanu AM. Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J Lipid Res. 1976;17:125-131[Abstract].
23.
Hakomori S, Igarashi Y.
Functional role of glycosphingolipids in cell recognition and signaling.
J Biochem.
1995;118:1091-1103 24. Skipski VP, Barclay M, Barclay RK, Fetzer VA, Good JJ, Archibald FM. Lipid composition of human serum lipoproteins. Biochem J. 1967;104:340-352[Medline] [Order article via Infotrieve].
25.
Deguchi H, Fernández JA, Hackeng TM, Banka CL, Griffin JH.
Cardiolipin is a normal component of human plasma lipoproteins.
Proc Natl Acad Sci U S A.
2000;97:1743-1748 26. Kundu SK. Thin-layer chromatography of neutral glycosphingolipids and gangliosides. Methods Enzymol. 1981;72:185-204[Medline] [Order article via Infotrieve].
27.
Wilkening G, Linke T, Sandhoff K.
Lysosomal degradation on vesicular membrane surfaces: enhanced glucosylceramide degradation by lysosomal anionic lipids and activators.
J Biol Chem.
1998;273:30271-30278 28. Clarke JT. The glycosphingolipids of human plasma lipoproteins. Can J Biochem. 1981;59:412-417[Medline] [Order article via Infotrieve].
29.
Chatterjee S.
Sphingolipids in atherosclerosis and vascular biology.
Arterioscler Thromb Vasc Biol.
1998;18:1523-1533
30.
Kalafatis M, Rand MD, Mann KG.
The mechanism of inactivation of human factor V and human factor Va by activated protein C.
J Biol Chem.
1994;269:31869-31880
31.
Rosing J, Hoekema L, Nicolaes MC, et al.
Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C.
J Biol Chem.
1995;270:27852-27858
32.
Solymoss S, Tucker MM, Tracy PB.
Kinetics of inactivation of membrane-bound factor Va by activated protein C: protein S modulates factor Xa protection.
J Biol Chem.
1988;263:14884-14890 33. Heeb MJ, Kojima Y, Hackeng TM, Griffin JH. Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va. Protein Sci. 1996;5:1883-1889[Medline] [Order article via Infotrieve].
34.
Thorelli E, Kaufman RJ, Dahlback B.
Cleavage of factor V at Arg506 by activated protein C and expression of anticoagulant activity of factor Va.
Blood.
1999;93:2552-2558 35. Bradley WA, Gianturco SH. Vitamin K-dependent proteins bind to very low-density lipoproteins. Semin Thromb Hemost. 1988;14:253-257[Medline] [Order article via Infotrieve].
36.
Moyer MP, Tracy RP, Tracy PB, van't Veer C, Sparks CE, Mann KG.
Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes.
Arterioscler Thromb Vasc Biol.
1998;18:458-465
37.
Xu N, Dahlbäck B, Ohlin AK, Nilsson A.
Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma.
Arterioscler Thromb Vasc Biol.
1998;18:33-39 38. Curvers J, Thomassen MC, Nicolaes GA, et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol. 1999;105:88-94[CrossRef][Medline] [Order article via Infotrieve]. 39. Cumming AM, Tait RC, Fildes S, Young A, Keeney S, Hay CR. Development of resistance to activated protein C during pregnancy. Br J Haematol. 1995;90:725-727[Medline] [Order article via Infotrieve].
40.
Shukla A, Shukla GS, Radin NS.
Control of kidney size by sex hormones: possible involvement of glucosylceramide.
Am J Physiol.
1992;262:F24-F29 41. Radin NS. Chemotherapy by slowing glucosphingolipid synthesis. Biochem Pharmacol. 1999;57:589-595[CrossRef][Medline] [Order article via Infotrieve]. 42. Cabot MC, Giuliano AE, Volner A, Han TY. Tamoxifen retards glycosphingolipid metabolism in human cancer cells. FEBS Lett. 1996;394:129-131[CrossRef][Medline] [Order article via Infotrieve]. 43. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol. 1998;45:608-612[CrossRef][Medline] [Order article via Infotrieve].
44.
Rosenberg RD, Aird WC.
Vascular-bed specific hemostasis and hypercoagulable states.
N Engl J Med.
1999;340:1555-1564
45.
Tans G, Rosing J, Griffin JH.
Sulfatide-dependent autoactivation of human blood coagulation factor XII (Hageman factor).
J Biol Chem.
1983;258:8215-8222
46.
Hara A, Kutsukaka Y, Uemura K, Taketomi T.
Anticoagulant activity of sulfatide and its antithrombotic effect in rabbit.
J Biochem.
1993;113:781-785
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  L. O. Mosnier, B. V. Zlokovic, and J. H. Griffin The cytoprotective protein C pathway Blood, April 15, 2007; 109(8): 3161 - 3172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Eichinger, N. M. Pecheniuk, G. Hron, H. Deguchi, M. Schemper, P. A. Kyrle, and J. H. Griffin High-Density Lipoprotein and the Risk of Recurrent Venous Thromboembolism Circulation, March 27, 2007; 115(12): 1609 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mineo, H. Deguchi, J. H. Griffin, and P. W. Shaul Endothelial and Antithrombotic Actions of HDL Circ. Res., June 9, 2006; 98(11): 1352 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Hemelsoet, A. Vantilborgh, J. L. De Bleecker, R. Schiffmann, D. F. Moore, and G. Altarescu Effect of genetic modifiers on cerebral lesions in Fabry disease Neurology, April 11, 2006; 66(7): 1131 - 1131. [Full Text] [PDF]
|
|
|
|
|
|
H. Deguchi, N. M. Pecheniuk, D. J. Elias, P. M. Averell, and J. H. Griffin High-Density Lipoprotein Deficiency and Dyslipoproteinemia Associated With Venous Thrombosis in Men Circulation, August 9, 2005; 112(6): 893 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Leiba, U Seligsohn, Y Sidi, D Harats, B A Sela, J H Griffin, A Livneh, N Rosenberg, I Gelernter, H Gur, et al. Thrombophilic factors are not the leading cause of thrombosis in Behcet's disease Ann Rheum Dis, November 1, 2004; 63(11): 1445 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Deguchi, S. Yegneswaran, and J. H. Griffin Sphingolipids as Bioactive Regulators of Thrombin Generation J. Biol. Chem., March 26, 2004; 279(13): 12036 - 12042. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yegneswaran, H. Deguchi, and J. H. Griffin Glucosylceramide, a Neutral Glycosphingolipid Anticoagulant Cofactor, Enhances the Interaction of Human- and Bovine-activated Protein C with Negatively Charged Phospholipid Vesicles J. Biol. Chem., April 18, 2003; 278(17): 14614 - 14621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R Deitcher and M. P. Gomes Hypercoagulable state testing and malignancy screening following venous thromboembolic events Vascular Medicine, February 1, 2003; 8(1): 33 - 46. [Abstract] [PDF]
|
|
|
|
|
|
S. R. Lentz, F. J. Miller Jr, D. J. Piegors, R. A. Erger, J. A. Fernandez, J. H. Griffin, and D. D. Heistad Anticoagulant Responses to Thrombin Are Enhanced During Regression of Atherosclerosis in Monkeys Circulation, August 13, 2002; 106(7): 842 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Oliver, D. M. Monroe, F. C. Church, H. R. Roberts, and M. Hoffman Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces Blood, June 28, 2002; 100(2): 539 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Deguchi, J. A. Fernandez, and J. H. Griffin Neutral Glycosphingolipid-dependent Inactivation of Coagulation Factor Va by Activated Protein C and Protein S J. Biol. Chem., March 8, 2002; 277(11): 8861 - 8865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Levade, N. Auge, R. J. Veldman, O. Cuvillier, A. Negre-Salvayre, and R. Salvayre Sphingolipid Mediators in Cardiovascular Cell Biology and Pathology Circ. Res., November 23, 2001; 89(11): 957 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. S. Arkel and D.-H. W. Ku State-of-the-Art Review: Thrombophilia and Pregnancy: Review of the Literature and Some Original Data Clinical and Applied Thrombosis/Hemostasis, October 1, 2001; 7(4): 259 - 268. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
80°C prior to analysis.
-napthol sugar
test.
) were
determined by HPLC analysis as described in "Patients, materials, and
methods." The clotting times (left ordinate) observed in the presence
(
) and absence (
) of APC:protein S are shown. The plasma GlcCer
level prior to glucocerebrosidase treatment was defined as
100%.
, GalCer; and 
, LacCer) and for baseline controls (without APC or
protein S added) (
, Gb3Cer; 
, GalCer; and
, LacCer). For GlcCer addition, clotting times are also shown for
addition of APC alone (
indicates GlcCer).
